US5733925A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic inhibitor of vascular smooth muscle cells
Assignee: UAB Research Foundation
•
Filing: 1996-10-28
•
Granted: 1998-03-31
•
Expires: 2016-10-28
Abstract
Abstract Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.
Inventors
- 👤 Lawrence L. Kunz
- 👤 Richard A. Klein
- 👤 John M. Reno
- 👤 David J. Grainger
- 👤 James C. Metcalfe
- 👤 Peter L. Weissberg
- 👤 Peter G. Anderson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 22:19
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/13; A61K31/135; A61K31/138; A61K31/33; A61K31/335; A61K31/337; A61K31/395; A61K31/40; A61K31/4025; A61K31/403; A61K31/4035; A61K31/407; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61K47/6811; A61K47/6817; A61K47/6831; A61K47/6835; A61K47/6843; A61K47/69; A61K47/6921; A61K47/6927; A61K47/6929; A61K47/6931; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/323
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
27 words
A therapeutic method comprising inhibiting stenosis or restenosis of a blood vessel by administering to a mammal an effective amount of taxol or a structural analog thereof.
Claim 2
Dependent Claim
27 words
A therapeutic method comprising inhibiting stenosis or restenosis of a blood vessel by administering to a mammal an effective amount of taxol or a structural analog thereof.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein an effective amount of taxol is administered.
Claim 4
Dependent Claim
12 words
The method of claim 1 or 2 wherein the administration is local.
Claim 5
Dependent Claim
12 words
The method of claim 3 wherein the administration is via a catheter.
Claim 6
Dependent Claim
12 words
The method of claim 1 or 2 wherein the administration is systemic.
Claim 7
Dependent Claim
10 words
The method of claim 5 wherein the administration is oral.
Claim 8
Dependent Claim
15 words
The method of claim 1 or 2 wherein vessel is subjected to procedural vascular trauma.
Claim 9
Dependent Claim
15 words
The method of claim 7 wherein the administration is before, during or after the trauma.
Claim 10
Dependent Claim
19 words
The method of claim 8 wherein the vascular trauma is associated with angioplasty, placement of a stent, or grafting.
Claim 11
Dependent Claim
18 words
The method of claim 1 wherein the amount is effective to inhibit proliferation of vascular smooth muscle cells.
Claim 12
Dependent Claim
16 words
The method of claim 1 wherein the administration is accomplished by a sustained release dosage form.
Claim 13
Dependent Claim
13 words
The method of claim 11 wherein the sustained release dosage form is biodegradable.
Claim 14
Independent Claim
39 words
A method for biologically stenting a mammalian blood vessel which is subjected to procedural vascular trauma, which method comprises administering to the blood vessel an amount of taxol or a structural analog thereof effective to biologically stent the vessel.
Claim 15
Independent Claim
39 words
A method for biologically stenting a mammalian blood vessel which is subjected to procedural vascular trauma, which method comprises administering to the blood vessel an amount of taxol or a structural analog thereof effective to biologically stent the vessel.
Claim 16
Dependent Claim
22 words
The method of claim 13 wherein the amount does not eliminate the ability of vascular smooth muscle cells to secrete extracellular matrix.
Claim 17
Dependent Claim
12 words
The method of claim 13 wherein the administration is by a catheter.
Claim 18
Dependent Claim
15 words
The method of claim 13 wherein the administration is before, during or after the trauma.
Claim 19
Dependent Claim
18 words
The method of claim 13 wherein the vessel is subjected to angioplasty, placement of a stent, or grafting.
Claim 20
Dependent Claim
10 words
The method of claim 13 wherein the administration is local.
Claim 21
Dependent Claim
9 words
The method of claim 13 wherein taxol is administered.
Claim 22
Dependent Claim
22 words
The method of claim 13 wherein the administration further comprises the administration of a sustained release dosage form comprising a cytoskeletal inhibitor.
Claim 23
Dependent Claim
65 words
A therapeutic method comprising: (a) administering to a blood vessel of a mammal traumatized by a surgical procedure an amount of taxol or a structural analog thereof effective to biologically stent the vessel; and (b) administering an amount of a sustained release dosage form comprising an amount of a cytostatic agent effective to inhibit proliferation of the cells of the vessel caused by said procedure.
Claim 24
Dependent Claim
65 words
A therapeutic method comprising: (a) administering to a blood vessel of a mammal traumatized by a surgical procedure an amount of taxol or a structural analog thereof effective to biologically stent the vessel; and (b) administering an amount of a sustained release dosage form comprising an amount of a cytostatic agent effective to inhibit proliferation of the cells of the vessel caused by said procedure.
Claim 25
Dependent Claim
10 words
The method of claim 21 wherein the administration is local.
Claim 26
Dependent Claim
21 words
The method of claim 21 wherein the cytostatic agent comprises cytochalasin B or a cytochalasin that is a functional analog thereof.
Claim 27
Dependent Claim
16 words
The method of claim 21 wherein the cytostatic agent comprises taxol or a structural analog thereof.
Claim 28
Dependent Claim
15 words
The method of claim 21 wherein the sustained release dosage form comprises microparticles or nanoparticles.
Claim 29
Dependent Claim
22 words
The method of claim 21 wherein the administration of taxol or a structural analog thereof is before, during or after the trauma.
Claim 30
Dependent Claim
24 words
The method of claim 26 wherein the administration of taxol or a structural analog thereof and the administration of the cytostatic agent is simultaneous.
Claim 31
Dependent Claim
18 words
The method of claim 21 wherein the administration of the cytostatic agent is before or after the trauma.
References Cited (Backward Citations)
US33403A
Cited
US32944A
Cited
USRE32944E
Cited
US3940422A
Cited
US4070484A
Cited
US4235988A
Cited
US5098903A
Cited
US5324736A
Cited
US4442119A
Cited
US5332584A
Cited
US5047431A
Cited
US4485096A
Cited
US5015666A
Cited
US4879315A
Cited
US4485097A
Cited
US4577636A
Cited
US4555402A
Cited
US4867973A
Cited
US5226430A
Cited
US5284763A
Cited
US4826672A
Cited
US5316766A
Cited
US4859585A
Cited
US4962091A
Cited
US5314679A
Cited
US4839155A
Cited
US5120535A
Cited
US4968350A
Cited
US5114719A
Cited
US5093330A
Cited
US4835002A
Cited
US5216024A
Cited
US5221620A
Cited
US4997652A
Cited
US5468746A
Cited
US5213580A
Cited
US5208019A
Cited
US5340925A
Cited
US5268358A
Cited
US5380716A
Cited
US5304541A
Cited
US5032679A
Cited
US5073633A
Cited
US5356713A
Cited
US5364632A
Cited
US5026537A
Cited
US5288735A
Cited
US5248764A
Cited
US5346897A
Cited
US5208238A
Cited
US5364843A
Cited
US5395610A
Cited
US5112305A
Cited
US5242397A
Cited
US5043335A
Cited
US4990538A
Cited
US5059166A
Cited
US5176617A
Cited
US5232911A
Cited
US5049132A
Cited
US5199939A
Cited
US5199939B1
Cited
US5328471A
Cited
US5260224A
Cited
US5140012A
Cited
US5166143A
Cited
US5189046A
Cited
US5189212A
Cited
US5192525A
Cited
US5219548A
Cited
US5238714A
Cited
US5053033A
Cited
US5180366A
Cited
US5362424A
Cited
US5308622A
Cited
US5102402A
Cited
US5171217A
Cited
US5280016A
Cited
US5116864A
Cited
US5254594A
Cited
US5213576A
Cited
US5296492A
Cited
US5229495A
Cited
US5216126A
Cited
US5185260A
Cited
US5304325A
Cited
US5270047A
Cited
US5284869A
Cited
US5238950A
Cited
US5326757A
Cited
US5354562A
Cited
US5346993A
Cited
US5280109A
Cited
US5444164A
Cited
US5288711A
Cited
US5283257A
Cited
US5393763A
Cited
US5460807A
Cited
US5346702A
Cited
US5354774A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-30 | 2001-09-29 | 2002-03-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-30 | 2005-09-29 | 2006-03-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-30 | 2009-09-29 | 2010-03-31 | $7700.00 | Window Closed / Lapsed |